Tanreqing injection auxiliary in the treatment of heart failure with pulmonary infection: A systematic review

Objective: To systematically evaluate the clinical efficacy and safety of Tanreqing injection in the treatment of heart failure complicated with pulmonary infection. Methods: The database of CNKI, SinoMed, VIP full text database, Wanfang database, Cochrance Library, Web of Science and PubMed were searched. The retrieval time was from the inception to August 2021. Clinical randomized controlled trial of Tanreqing injection in the treatment of heart failure complicated with pulmonary infection was collected, and two researchers independently screened the document data. Meta-analysis was performed using RevMan 5.4.1 software. Results: A total of 10 documents were included, including 862 cases of heart failure complicated with pulmonary infection, including 431 cases in the test group, and 431 cases in the control group. The Meta analysis showed that compared to the control group, the test group increased clinical efficiency [OR=4.56, 95％ CI(2.79, 7.52), P<0.00001], reduced the value of C-reactive protein [MD =-7.55, 95％ CI (- 11.40, -3.69), P=0.0001], reduced the time required to correct heart failure [OR=-4.04, 95％ CI (-4.59, -3.49), P<0.00001], reduced the number of days of the average hospitalization [MD =-4.78, 95％CI (-6.67, -2.89), P<0.00001], and there were no statistically significant differences in the incidence of adverse reactions. Conclusion: Tanreqing injection, as an auxiliary treatment for heart failure complicated with pulmonary infection, has significantly effective effect on improving efficiency. Tanreqing injection has a certain advantage in reducing C-creative protein values, shortening the time of correcting heart failure, and reducing the number of days of the average hospitalization, and the adverse reactions are smaller. However, the overall quality of the included studies is low, and more high-quality randomized controlled trials are needed to increase the evidence-based basis.